Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1609-6000
Debt
Debt-to-Equity Ratio0.45
Current Ratio1.14
Quick Ratio0.66
Price-To-Earnings
Trailing P/E Ratio10.68
Forward P/E Ratio10.60
P/E Growth1.35
Sales & Book Value
Annual Sales$15.16 billion
Price / Sales3.24
Cash Flow$22.6364 per share
Price / Cash7.15
Book Value$119.43 per share
Price / Book1.36
Profitability
EPS (Most Recent Fiscal Year)$15.15
Net Income$4.27 billion
Net Margins28.96%
Return on Equity13.60%
Return on Assets6.92%
Miscellaneous
Employees23,044
Outstanding Shares303,950,000
Shire (NASDAQ:SHPG) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire pay dividends? What is the dividend yield for Shire?
Shire declared a semiannual dividend on Friday, February 16th. Investors of record on Friday, March 9th will be paid a dividend of $0.8937 per share on Tuesday, April 24th. This represents a yield of 1.33%. The ex-dividend date is Thursday, March 8th. This is a positive change from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.
How were Shire's earnings last quarter?
Shire PLC (NASDAQ:SHPG) issued its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a net margin of 28.96% and a return on equity of 13.60%. Shire's revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.63 EPS. View Shire's Earnings History.
When is Shire's next earnings date?
What guidance has Shire issued on next quarter's earnings?
Shire updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.23. The company issued revenue guidance of $15.4-15.9 billion, compared to the consensus revenue estimate of $15.48 billion.
What price target have analysts set for SHPG?
17 brokers have issued 12-month price objectives for Shire's shares. Their predictions range from $150.00 to $245.00. On average, they anticipate Shire's share price to reach $201.6429 in the next twelve months. View Analyst Ratings for Shire.
What are Wall Street analysts saying about Shire stock?
Here are some recent quotes from research analysts about Shire stock:
- 1. According to Zacks Investment Research, "Sales of Shire’s Mydayis showed promise in the first six months of launch. Also, strong performance of Vyvanse, Cinryze and Elaprase continue to drive its top line. The label expansion of Firazyr in pediatrics and approval of Lyophilized Oncaspar in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. Though the adult ADHD space is one of the largest and fastest growing segments of the market, it is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2018)
- 2. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)
- 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)
Are investors shorting Shire?
Shire saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 1,853,536 shares, an increase of 40.6% from the May 15th total of 1,318,376 shares. Based on an average trading volume of 1,287,297 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.6% of the company's stock are sold short. View Shire's Current Options Chain.
Who are some of Shire's key competitors?
Some companies that are related to Shire include Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Sanofi (SNY), Bayer (BAYRY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
- Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
- Gisele Dion, Chief Accounting Officer
- Mr. Matthew Walker, Head of Technical Operations (Age 54)
- Prof. Andreas Busch Ph.D., Head of R&D & Chief Scientific Officer (Age 55)
Has Shire been receiving favorable news coverage?
Media headlines about SHPG stock have been trending somewhat negative this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire earned a news impact score of -0.18 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Shire's major shareholders?
Shire's stock is owned by a variety of of retail and institutional investors. Top institutional investors include The Manufacturers Life Insurance Company (0.61%), Northern Trust Corp (0.34%), BlackRock Inc. (0.30%), Rockefeller Capital Management L.P. (0.25%), New South Capital Management Inc. (0.22%) and Delek Group Ltd. (0.08%). View Institutional Ownership Trends for Shire.
Which major investors are selling Shire stock?
SHPG stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Point72 Asset Management L.P., MD Sass Investors Services Inc., BlackRock Inc., Guggenheim Capital LLC, PNC Financial Services Group Inc., Van ECK Associates Corp and Eagle Global Advisors LLC. View Insider Buying and Selling for Shire.
Which major investors are buying Shire stock?
SHPG stock was bought by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Prosight Management LP, Delek Group Ltd., Sphera Funds Management LTD., Dimensional Fund Advisors LP, First Light Asset Management LLC, Forsta AP Fonden and Sector Gamma AS. View Insider Buying and Selling for Shire.
How do I buy shares of Shire?
Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Shire's stock price today?
One share of SHPG stock can currently be purchased for approximately $161.85.
How big of a company is Shire?
Shire has a market capitalization of $49.36 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.
How can I contact Shire?
Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]
MarketBeat Community Rating for Shire (SHPG)
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
